Drug Trial Radar · NCT05293964
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
214
Actual
Start
May 18, 2022
Primary completion
Dec 31, 2024
Study completion Sep 8, 2025
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Nanjing Zaiming Pharmaceutical Co., Ltd.
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
SIM0270Drug
SIM0270 is an oral, selective estrogen receptor degrader (SERD)
PalbociclibDrug
palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
everolimusDrug
Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated DoseTime frame: At the end of Cycle 1 (each cycle is 28 days)
- recommended phase 2 DoseTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Dose-Limiting ToxicitiesTime frame: At the end of Cycle 1 (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.